异柠檬酸脱氢酶野生型胶质母细胞瘤再程放疗后的结局
单中心回顾性分析88例确诊IDH野生型胶质母细胞瘤再程放疗患者,中位总生存8.0个月,中位无进展生存5.9个月; multivariable Cox回归显示全切除对比活检或未切除对OS有正向影响(HR 0.43,p=0.02);随访期内未记录到明确的放射性坏死证据。
要点
- 88例IDH野生型胶质母细胞瘤再程放疗后中位OS为8.0个月,中位PFS为5.9个月。
- multivariable Cox回归显示全切除对比活检或未切除与OS改善相关(HR 0.43,p=0.02)。
- 随访期内未记录到明确的放射性坏死证据,仅4例再放疗后接受手术,均无放射性坏死组织病理学证据。
核心结论
- 复发IDH野生型胶质母细胞瘤再程放疗后预后差,能够并适合接受再切除的患者可能有较好的OS。
- 再程放疗采用中等累积EQD2和中小型计划靶区在放射性坏死发生方面似乎安全。
研究设计与样本
- 单中心回顾性分析,纳入确诊IDH野生型并接受再程放疗的胶质母细胞瘤患者,共88例。
主要发现
- 中位临床随访4.6个月,中位影像学随访4.4个月。
- 多数患者卡氏功能状态评分至少80%(n=57)。
- 再程放疗的中位生物有效剂量为51.4 Gy,中位2 Gy等效剂量(EQD2)为42.8 Gy(假设胶质母细胞瘤α/β比为10 Gy)。
- 共记录71例死亡,中位总生存(OS)为8.0个月,中位无进展生存(PFS)为5.9个月。
- OS的多变量Cox回归显示全切除对比活检或未切除有正向影响(风险比:0.43,p=0.02);PFS的多变量Cox回归未发现显著因素。
关键数值与推荐
- 再程放疗中位生物有效剂量51.4 Gy,中位EQD2 42.8 Gy(α/β=10 Gy)。
- OS多变量Cox回归:全切除对比活检或未切除的风险比0.43(p=0.02)。
- 随访期内未记录到明确的放射性坏死证据;仅4例再放疗后接受手术,均无放射性坏死组织病理学证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastomas (GBM) are the most common malignant primary brain tumors in adults and have a dismal prognosis. Patients frequently suffer from local tumor recurrences, with limited therapeutic options. Re-irradiation represents a possible intervention, but given the recent 5th edition of the World Health Organization classification of central nervous system tumors, studies in isocitrate dehydrogenase wild type (IDH-wt) cohorts undergoing a second course of radiotherapy remain limited. Herein, we sought to describe our institutional experience and outcomes after GBM IDH-wt re-irradiation. MATERIALS AND METHODS: GBM patients with confirmed IDH-wt status undergoing re-irradiation were included in this single-center, retrospective analysis. RESULTS: A total of 88 patients were analyzed. The median clinical and radiographic follow-up periods were 4.6 months and 4.4 months, respectively. Most patients had a Karnofsky performance status of at least 80% (n = 57). The median biologically effective dose and 2 Gy equivalent dose (EQD2) for re-irradiations, assuming an α/β ratio of 10 Gy for GBM, were 51.4 and 42.8 Gy, respectively. In total, 71 deaths were recorded. The median overall survival (OS) was 8.0 months. Multivariable Cox regression of OS revealed a positive influence of gross total resection vs. biopsy or no resection (hazard ratio: 0.43, p = 0.02). The median progression-free survival (PFS) was 5.9 months. The multivariable Cox regression for PFS did not detect any significant factors. No clear evidence of radiation necrosis was recorded during the available follow-up. However, only a minority (n = 4) of patients underwent surgery after re-irradiation, none showing histopathological proof of radiation necrosis. CONCLUSION: The prognosis for recurrent IDH-wt GBM after re-irradiation is poor. Patients who are amenable and able to undergo re-resection may have a favorable OS. A second course of radiotherapy with a moderate cumulative EQD2 and small- to medium-sized planning target volumes appeared safe regarding the occurrence of radiation necrosis.
引用
- Ehret F, Wolfgang J, Allwohn L, et al. Outcomes of Isocitrate Dehydrogenase Wild Type Glioblastoma after Re-irradiation. Clin Transl Radiat Oncol. 2023. PMID: 37502699. doi:10.1016/j.ctro.2023.100653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。